Frontlight ResearchEarly access
TerminatedNo phase
Fluoroquinolone Resistance Prevalence Study
Key facts
- Who runs it
- Hackensack Meridian Health
- Where
- Hackensack and Washington D.C., United StatesSee the 2 sites
- Trial code
- Status
- Terminated
- People taking part
- 124 people enrolled
- Started
- 8 Jul 2022
- Ended
- 15 Jan 2025
- Type of study
- Observational
- Record updated
- 5 June 2026
- Why it stopped
- Discontinued Recruitment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Subjects >18 yrs of age
- Diagnosis of multiple myeloma undergoing (first or subsequent) autologous PBSC transplantation
- Transplant conditioning with melphalan 200 mg/m2
- PBSC cell dose of >2x10e6 CD34+ cells/kg
- Able to receive fluoroquinolone prophylaxis
- Subjects must give consent for enrollment into this study
Who cannot take part
- Receiving a conditioning regimen other than melphalan 200 mg/m2
- Unwillingness to provide informed consent
- Enrollment into a treatment protocol prescribing antibiotic prophylaxis
- A diagnosis other than multiple myeloma
- Known light-chain amyloid deposition in any organ
Where in United States
- John Theurer Cancer Center/ Hackensack Meridian HealthHackensack, United States
- Lombardi Comprehensive Cancer Center, Georgetown UniversityWashington D.C., United States
About the trial
What the trial wants to find out
This is an exploratory study to determine the prevalence of fluoroquinolone resistance in patients receiving dose-intense melphalan with autologous peripheral blood stem cell (PBSC) transplantation in the treatment of multiple myeloma (MM).
Read full original descriptionShow less
These data may be used in subsequent studies exploring the use of prophylaxis in this patient population.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Exploratory Study of Fluoroquinolone Resistance for Patients Undergoing Autologous Hematopoietic Stem Cell (HSC) Transplantation in the Treatment of Multiple Myeloma
- Record updated
- 5 June 2026